Online inquiry

IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ801MR)

This product GTTS-WQ801MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets AXL gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001278599.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 558
UniProt ID M0R0W6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ801MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13956MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ9559MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ7011MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ11049MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ5337MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ822MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ14129MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ7427MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GBR500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW